Articles Tagged With:
-
Even integrated systems may need specialized revenue cycle software
Integrated systems can solve many dilemmas for patient access by creating work lists for error management and allowing staff to determine eligibility in real time.
-
Warning: ED Peer Review Materials Aren’t Always Protected from Discovery
Many emergency physicians (EPs) assume that all aspects of the peer review or quality improvement processes involving emergency department (ED) care are automatically protected from discovery during malpractice litigation. This is not necessarily the case.
-
Nurse Fatigue a ‘Huge’ Threat to Patient Safety
Risk managers should adopt strategies to reduce fatigue caused by scheduling, overtime, and excessive workloads.
-
Integrated systems are top priority — Dramatically improve efficiency
It’s one of the biggest time-wasters in patient access: Employees are constantly switching back and forth between many different systems, just to do their jobs.
-
Anticoagulant Linked to Lower Risk of Bleeding in Certain MI Patients
These events are associated with mortality in patients with non-ST-segment elevation myocardial infarction. Find out what reduced the risk.
-
Here Are Plaintiff Attorneys’ Toughest Deposition Questions for Emergency Physicians
Did an emergency physician (EP) come off poorly during a deposition, volunteer some damaging information, or inadvertently complicate the defense of a co-defendant? If so, “it will significantly change the perspective of the defense attorney, the hospital, or the insurance company on whether the case should settle and for how much, in a way that’s going to be adverse to the EP,” warns John Burton, MD, chair of the Department of Emergency Medicine at Carilion Clinic in Roanoke, VA.
-
Recognizing Human Trafficking Victims in the Emergency Department
You may have seen a case of human trafficking and not recognized it. Emergency physicians can play a role in identifying victims and mobilizing resources for them.
-
Peramivir: A Newly Approved Antiviral for Treatment of Influenza
Peramivir (Rapivab™) was recently approved by the FDA in December 2014 for treatment of acute uncomplicated influenza within two days of symptom onset. This newly approved antiviral is a neuraminidase inhibitor (NI) similar to oseltamivir and zanamivir but the first to be approved in an injectable formulation.1 Peramivir has been licensed in Japan (as Rapiacta) and South Korea (as PeramiFlu) since 2010. In addition, it has been used in the United States on an emergency basis during the 2009 H1N1 flu pandemic.
-
Report from the International Stroke Conference 2015
Major announcements at the International Stroke Conference 2015 in Nashville, Tennessee, included reports on three trials that compared endovascular clot retrieval for acute ischemic stroke, compared to medical treatment with intravenous thrombolytics alone. -
Intracranial Hemorrhage Risk: Are Novel Oral Anticoagulants Better Than Warfarin?
Clinicians have commonly overestimated the risk of intracerebral hemorrhage (ICH) during anticoagulant therapy. Indeed, such misapprehensions have sometimes led to failure to employ warfarin (and probably other agents) when indicated for atrial fibrillation.